December 20, 2017<\/p>\n
Data Integration Services Crucial to Decision Support in Oncology<\/p>\n
NEW YORK; Dec. 20, 2017 \u2013 Accenture (NYSE: ACN) today announced a collaborative services agreement with Roche. Under the terms of this exclusive multi-year agreement, Accenture will provide digital data integration services to Roche\u2019s NAVIFY Tumor Board solution.<\/p>\n
A tumor board is a meeting in which multi-disciplinary healthcare teams review and discuss individual cancer patient cases and available treatment options. The NAVIFY Tumor Board solution streamlines and standardizes the tumor board workflow process by aggregating relevant patient data from disparate IT systems into a software solution that fosters efficient team collaboration, reduces errors, and gives the care team more time to evaluate individual patient cases.<\/p>\n
The data integration capabilities Accenture provides will allow Roche to integrate patient data between hospitals and the NAVIFY Tumor Board solution to support clinicians in arriving at the best possible treatment decisions for their patients. The NAVIFY Tumor Board solution is built on a secure cloud platform.<\/p>\n
\u201cOur collaboration with Accenture is another exciting step forward in providing personalized healthcare solutions to patients,\u201d said Tim M. Jaeger, Global Head of Diagnostics Information Solutions for Roche. \u201cTumor board coordination is labor intensive and time consuming for healthcare providers. Accenture\u2019s global scale, deep digital expertise, and innovation capabilities in the healthcare and life sciences industries allows Roche to continue our focus on delivering workflow and decision support solutions to customers and improving patient outcomes.\u201d<\/p>\n
Andrea Br\u00fcckner<\/a>, who leads Accenture\u2019s Life Sciences practice in Europe, said: \u201cWith Roche, we continue to provide meaningful impact on patients\u2019 lives by combining new science with leading-edge technology to revolutionize patient care. By providing data integration services to the NAVIFY Tumor Board solution, we aim to ensure that all available data is used to accelerate and optimize treatment decisions for cancer patients.\u201d<\/p>\n As shared in an October 2017 announcement<\/a>, the NAVIFY Tumor Board solution fundamentally changes the way tumor board meetings are organized and conducted with the goal of fostering collaboration on patient treatment decisions. It is currently available in the US, UK, Germany, Spain, Sweden, Switzerland, and the Netherlands.<\/p>\n About Accenture Accenture Disclaimer: # # #<\/p>\n Contact:<\/p>\n
Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions \u2013 underpinned by the world\u2019s largest delivery network \u2013 Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With approximately 425,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com<\/a>.<\/p>\n
Accenture is in no way promoting or intending to provide a medical device or recommend a product for purposes of any diagnosis or treatment. Accenture expects Roche and other companies involved to use its own operations to ensure compliance with applicable laws and regulations.<\/p>\n